The invention provides multispecific antibodies and methods of making and using such antibodies.

The invention generally relates to immunotherapy using immune cells such as chimeric antigen receptor (CAR)-engineered T cells. In particular, the invention relates to immunotherapy using chimeric antigen receptor (CAR)-engineered T cells that carry a novel, IgG3-Hinge-based spacer domain, allowing a finely modulated response to target antigens. In addition, the invention relates to the introduction of one or more IgG3-Hinge-based multi-function sites (MFs) into CARs and other immunoreceptors, allowing purification, stimulation, expansion and depletion of CAR T cells. The invention includes also the sequence of an antibody targeting this motif, allowing the execution of the before-mentioned functions.

In general, the invention features a novel CBM32-derived affinity scaffold. In certain embodiments, the scaffold comprises two types of regions: constant regions (CRs) and variable loop regions (VLRs) as depicted in the structure in FIG. 1. We have discovered that the CRs provide structural features that enable overall conformational stability while the intervening sequences corresponding to VLRs tolerate amino acid sequence randomization.

The present invention describes novel 7-alkylamino-3-(thienyl) coumarin fluorescent dyes of formula (I)

##STR00001##

These dyes are water soluble, can be excited by the 405 nm excitation source and exhibit a large Stokes shift (≧80 nm). Furthermore, the dyes possess a reactive group for the labeling of biomolecules or other analytes.

Herein are reported a monoclonal antibody specifically binding to a human IgG1 antibody and not specifically binding to the immunoglobulin of an experimental animal and the use of the antibody in immunoassays.

Disclosed are lateral flow assay methods, lateral flow assay test strips, and devices for detection of antibody classes associated with acute immune responses. The invention generally relates to assay methods, in particular, lateral flow assay methods for detection of an antibody isotype associated with acute infection, and to lateral flow assay strips for use in the methods of the invention.

Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein.

This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference and/or give rise to an (aspecific) signal in such an assay (such as in an ADA immunoassay; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

Disclosed is a calibrator comprising IgA having a biotin group and a biotin-binding site, the calibrator being used to obtain a concentration of an IgA aggregate in a sample.

The disclosure provides an antibody, a composition for use in detecting or capturing a polypeptide in a sample, and a method for detecting or capturing a polypeptide in sample.